Serina Therapeutics, Inc. (SER)

Serina Therapeutics, Inc. (SER) Healthcare & Pipeline Overview

Serina Therapeutics, Inc. is a biotechnology firm specializing in the development of novel therapeutics for neurological disorders and pain management, leveraging its proprietary POZ conjugate technology. Their lead candidate, SER 252, aims to address Parkinson's disease, positioning them in the competitive biotechnology landscape.

What Is the Investment Thesis for SER?

Serina Therapeutics presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's proprietary POZ conjugate technology offers a novel approach to drug delivery, potentially enhancing the efficacy and reducing the side effects of existing treatments. The lead candidate, SER 252, targeting Parkinson's disease, represents a significant market opportunity. However, the company's negative profit margin of -14755.4% indicates substantial reliance on future clinical trial success and potential partnerships. Successful clinical trials and subsequent regulatory approvals are critical for realizing the value of Serina's pipeline. The company's small size and limited resources also pose challenges to its ability to advance multiple programs simultaneously. The low Beta of 0.10 suggests low volatility relative to the market.

Based on FMP financials and quantitative analysis

SER Key Highlights

• Market capitalization of $21.83M, indicating a small-cap company with potential for growth but also higher risk.
• Gross margin of 43.8%, suggesting efficient cost management in its operations.
• Profit margin of -14755.4%, reflecting significant investment in research and development and the absence of revenue-generating products.
• Lead product candidate, SER 252, targeting Parkinson's disease, a large and underserved market.
• Proprietary POZ conjugate technology platform, offering a potential competitive advantage in drug delivery.

Who Are SER's Competitors?

SER is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are SER's Key Strengths?

• Proprietary POZ conjugate technology platform.
• Pipeline of drug candidates targeting neurological diseases and pain.
• Experienced management team with expertise in drug development.
• Focus on unmet medical needs.

What Are SER's Weaknesses?

• Limited financial resources.
• Small size and limited infrastructure.
• Dependence on successful clinical trial outcomes.
• High attrition rate in drug development.

What Could Drive SER Stock Higher?

• Data readout from ongoing clinical trials of SER 252 for Parkinson's disease (expected in the next 12-18 months).
• Initiation of clinical trials for SER 227 for long-acting pain relief (expected in the next 12-24 months).
• Progress in preclinical development of SER 214 and SER 228 for neurological disorders.
• Potential partnerships and collaborations with pharmaceutical companies.

What Are the Key Risks for SER?

• Financial-distress signal — its Altman Z-Score of -4.01 sits in the distress zone (elevated bankruptcy risk).
• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures for SER 252 or other pipeline candidates.
• Regulatory delays or rejection of drug approval applications.
• Competition from established pharmaceutical companies and other biotechnology firms.
• Limited financial resources and dependence on external funding.
• Patent challenges and intellectual property disputes.

What Are the Growth Opportunities for SER?

• Expansion of SER 252 clinical trials: Advancing SER 252 through clinical trials represents a significant growth opportunity. Positive clinical results could lead to regulatory approval and commercialization, capturing a portion of the Parkinson's disease treatment market, estimated to reach $5.6 billion by 2028. Successful trials would validate the POZ conjugate technology and attract potential partnerships or acquisitions. Timeline: Ongoing clinical trials with potential data readouts in the next 12-24 months.
• Development of SER 227 for long-acting pain relief: SER 227 targets the chronic pain market, a substantial and growing area with increasing demand for non-opioid alternatives. Successful development and commercialization of SER 227 could generate significant revenue and establish Serina as a player in the pain management space. The global pain management market is projected to reach $83 billion by 2027. Timeline: Preclinical and early clinical development over the next 2-3 years.
• Advancement of SER 214 and SER 228 for neurological disorders: Progressing SER 214 for Parkinson's disease and SER 228 for epilepsy through preclinical and clinical studies offers additional growth avenues. These programs leverage the POZ conjugate technology to address unmet needs in these neurological conditions. The epilepsy therapeutics market is expected to reach $12.4 billion by 2029. Timeline: Preclinical and early clinical development over the next 3-5 years.
• Partnerships and collaborations: Forming strategic partnerships with pharmaceutical companies or other biotechnology firms can provide Serina with access to funding, expertise, and resources to accelerate the development and commercialization of its pipeline. Collaborations can also validate the POZ conjugate technology and expand its applications. Timeline: Ongoing efforts to establish partnerships, with potential deals in the next 12-18 months.
• Application of POZ technology in RNA vaccines: Utilizing the POZ technology in lipid nanoparticle-delivered RNA vaccines for infectious diseases represents a longer-term growth opportunity. This application could expand Serina's reach beyond neurological disorders and pain management into the broader vaccine market. The global RNA vaccines market is projected to reach $25 billion by 2030. Timeline: Research and development phase over the next 3-5 years, with potential for clinical trials and commercialization in the longer term.

What Opportunities Does SER Have?

• Strategic partnerships with pharmaceutical companies.
• Expansion of POZ technology into new therapeutic areas.
• Advancement of pipeline candidates through clinical trials.
• Potential for regulatory approvals and commercialization.

What Threats Does SER Face?

• Competition from established pharmaceutical companies.
• Regulatory hurdles and delays.
• Clinical trial failures.
• Patent challenges and intellectual property disputes.

What Are SER's Competitive Advantages?

• Proprietary POZ conjugate technology platform.
• Pipeline of drug candidates targeting unmet needs in neurological diseases and pain management.
• Intellectual property protection for its technologies and drug candidates.
• Expertise in drug delivery and formulation.

What Does SER Do?

Founded in 2006 and based in Huntsville, Alabama, Serina Therapeutics, Inc. is a biotechnology company dedicated to creating innovative treatments for neurological diseases and pain. The company's core technology revolves around its proprietary POZ conjugate platform, which is designed to enhance drug delivery and efficacy. Serina's lead product candidate, SER 252, is a POZ conjugate specifically developed for the treatment of Parkinson's disease. In addition to SER 252, Serina is also developing SER 227 for long-acting pain relief, SER 214 for Parkinson's disease, and SER 228 for the treatment of epilepsy. The company is also exploring the application of its POZ technology in lipid nanoparticle-delivered ribonucleic acid (RNA) vaccines for infectious diseases. Serina Therapeutics aims to improve patient outcomes by addressing unmet medical needs in neurological disorders and pain management through advanced drug delivery technologies.

What Products and Services Does SER Offer?

• Develop drugs to treat neurological diseases.
• Create therapeutics for pain management.
• Utilize POZ conjugate technology for enhanced drug delivery.
• Develop SER 252 for the treatment of Parkinson's disease.
• Develop SER 227 for long-acting pain relief.
• Develop SER 214 to treat Parkinson's disease.
• Develop SER 228 for the treatment of epilepsy.
• Explore POZ technology in RNA vaccines for infectious diseases.

How Does SER Make Money?

• Focus on research and development of novel therapeutics.
• Utilize proprietary POZ conjugate technology to improve drug delivery.
• Seek partnerships and collaborations to advance pipeline development.
• Generate revenue through potential licensing agreements and future product sales.

What Industry Does SER Operate In?

Serina Therapeutics operates within the biotechnology industry, a sector characterized by high innovation, intense competition, and significant regulatory hurdles. The market for neurological disease treatments is substantial and growing, driven by an aging population and increasing prevalence of conditions like Parkinson's disease and epilepsy. Serina's POZ conjugate technology aims to differentiate it from competitors by offering improved drug delivery and efficacy. The company faces competition from established pharmaceutical companies and other biotechnology firms developing novel therapies for neurological disorders and pain management. Success in this industry requires strong scientific expertise, effective clinical trial execution, and strategic partnerships.

Who Are SER's Key Customers?

• Patients suffering from neurological diseases such as Parkinson's disease and epilepsy.
• Patients requiring pain management solutions.
• Pharmaceutical companies seeking innovative drug delivery technologies.
• Healthcare providers prescribing treatments for neurological disorders and pain.

How Serina Therapeutics, Inc. Is Valued

Serina Therapeutics, Inc. carries a market capitalization of $21.83M, placing it in the micro-cap category. Relative to its peer group, SER's quantitative score of 19/100 is below the peer average of 76/100.

Key Financial Metrics

Return on assets is -77.9%, showing how much profit it generates from its asset base. Its free cash flow yield is -86.8%, a gauge of the cash the business throws off relative to its market value. A current ratio of 4.18 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -91.0%, the inverse of the P/E and a quick read on earnings relative to price.

F-Score 3/9Financial Health

Serina Therapeutics, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -4.01 places it in the distress zone, a signal of elevated financial risk.

FY2026 estForward Outlook

Wall Street analysts project Serina Therapeutics, Inc. revenue of about $0 for fiscal 2026, with EPS near $-1.95.

SER Financials

SER Latest News

SER Analyst Consensus

SER MoonshotScore

Latest Serina Therapeutics, Inc. Analysis

SER Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources